Zobrazeno 1 - 10
of 164
pro vyhledávání: ''
Autor:
Sebastian Stintzing, Dominik Paul Modest, Volker Heinemann, T. Kirchner, Alexander Kiani, Andreas Jung, Dan Aderka, Thomas Decker, Frank Kullmann, L. Fischer von Weikersthal, Werner Scheithauer, Pratyaksha Wirapati, Tobias Heintges, Christian A. Lerchenmuller, H. J. Lenz, Daniel Neureiter, Markus Moehler, G. Seipelt, Sabine Tejpar, Christoph Kahl, S-E. Al-Batran, Swantje Held, Florian Kaiser
Publikováno v:
Annals of Oncology
BACKGROUND: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to
Autor:
Axel Grothey, Rachel Kerr, A. de Gramont, Takayuki Yoshino, Thierry André, Julien Taieb, Greg Yothers, Q. Shi, E. Van Cutsem, Aziz Zaanan, Steven R. Alberts, Levi Pederson, Sara Lonardi, Norman Wolmark, Frank A. Sinicrope
Publikováno v:
Annals of Oncology. 30:1466-1471
Microsatellite instable/deficient mismatch repair (MSI/dMMR) metastatic colorectal cancers have been reported to have a poor prognosis. Frequent co-occurrence of MSI/dMMR and BRAFV600E complicates the association.Patients with resected stage III colo
Autor:
Niall C. Tebbutt, John M. Mariadason, David S. Williams, Timothy J. Price, Daniel D. Buchanan, Jennifer Mooi, Chee Khoon Lee, Amanda R. Townsend, Jennifer E. Hardingham, Pratyaksha Wirapati, Rebecca Asher, Sabine Tejpar, P S Savas
Publikováno v:
Annals of Oncology. 29:2240-2246
Background: The consensus molecular subtypes (CMS) is a transcriptome-based classification of colorectal cancer (CRC) initially described in early-stage cohorts, but the associations of CMS with treatment outcomes in the metastatic setting are yet to
Autor:
Yoshino, Takayuki, Portnoy, D. C., Obermannová, R., Bodoky, G., Prausová, J., García-Carbonero, Rocío, Ciuleanu, Tudor Eliade, García-Alfonso, Pilar, Cohn, A. L., Van Cutsem, E., Yamazaki, K., Lonardi, Sara, Muro, K., Kim, T. W., Yamaguchi, K., Grothey, A., O'Connor, J., Taieb, J., Wijayawardana, S. R., Hozak, R. R., Nasroulah, F., Tabernero, J., Vall d'Hebron Institut d'Oncologia
Publikováno v:
Annals of Oncology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Carcinoma colorrectal; Ramucirumab; BRAF Carcinoma colorrectal; Ramucirumab; BRAF Colorectal carcinoma; Ramucirumab; BRAF Background Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients wit
Autor:
Ute Ohnmacht, C. Le Tourneau, Gerard J. Oakley, Christophe Massard, Analia Azaro, Jordi Rodon, Debashis Sarker, Karim A. Benhadji, Bharvin K. R. Patel, Ulrik Lassen, Claire Smith, Eunice Yuen, Jean-Charles Soria
Publikováno v:
Massard, C, Azaro, A, Soria, J C, Lassen, U, Le Tourneau, C, Sarker, D, Smith, C, Ohnmacht, U, Oakley, G, Patel, B K R, Yuen, E S M, Benhadji, K A & Rodon, J 2018, ' First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer ', Annals of Oncology, vol. 29, no. 9, pp. 1911-1917 . https://doi.org/10.1093/annonc/mdy244
Background Deregulated Notch signaling due to mutation or overexpression of ligands and/or receptors is implicated in various human malignancies. γ-Secretase inhibitors inhibit Notch signaling by preventing cleavage of transmembrane domain of Notch
Autor:
Gerhard G. Grabenbauer, Claus Rödel, E. Fokas, Rainer Fietkau, Torsten Liersch, Gunnar Folprecht, Ullrich Graeven, Werner Hohenberger, R.D. Hofheinz, Dirk Arnold, Michael Ghadimi, Marco Kaufmann, Rolf Sauer, Torsten Hothorn
Publikováno v:
Annals of Oncology. 29:1793-1799
The German rectal cancer trial CAO/ARO/AIO-04 has shown a significant benefit in 3-year disease-free survival (DFS) of adding oxaliplatin to a standard preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) and adjuvant chemotherapy in pati
Autor:
J. B. Fan, M. Bibikova, Haojie Huang, R. Shen, Hyunseon C. Kang, B. Barnes, Filip Janku, S. L. Moulder, E. S. Kopetz, Rodabe N. Amaria, Charles Lu, Toshinori Hinoue, Peter W. Laird, Hui Shen, Vivek Subbiah, K. Gutekunst, G. Granger, Li Liu, Sarina Anne Piha-Paul, David S. Hong, A. F. Jassowicz, Siquing Fu, Apostolia-Maria Tsimberidou, Neeraj Salathia, Raakhee Vijayaraghavan, Cathy Eng, Ruoyu Zhang, Aung Naing, K. M. Kruglyak, Funda Meric-Bernstam, J. M. Toung
Publikováno v:
Annals of Oncology. 29:1445-1453
Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a potential to expand liquid biopsies to patients with tumors without detectable oncogenic alterations, which can be potentially useful in early diagnosis.We developed a comprehensiv
Autor:
Susana Inogés, Ignacio Gil-Bazo, L. Resano, Pedro Berraondo, A.M. Salazar, Benigno Barbés, Guiomar Perez, C. De Andrea, Salvador Martín-Algarra, Mariano Ponz-Sarvise, Miguel F. Sanmamed, Ignacio Melero, A. Lopez-Diaz de Cerio, Carmen Oñate, Carlos Alfaro, Maria E. Rodriguez-Ruiz, Amparo Benito, Alfonso Gurpide, Jose Luis Perez-Gracia, Inmaculada Rodriguez
Publikováno v:
Annals of Oncology. 29:1312-1319
Background Combination immunotherapy has the potential to achieve additive or synergistic effects. Combined local injections of dsRNA analogues (mimicking viral RNA) and repeated vaccinations with tumor-lysate loaded dendritic cells shows efficacy ag
Autor:
Benny Vittrup Jensen, Brita Singers Sørensen, Dorte Nielsen, Anders Kindberg Boysen, R. Abrantes, K.-L. Spindler, Julia S. Johansen, Finn Larsen, Jakob Hagen Vasehus Schou
Publikováno v:
Schou, J V, Larsen, F O, Sørensen, B S, Abrantes, R, Boysen, A K, Johansen, J S, Jensen, B V, Nielsen, D L & Spindler, K L 2018, ' Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer ', Annals of Oncology, vol. 29, no. 3, pp. 610-615 . https://doi.org/10.1093/annonc/mdx778
Background: Treatment of patients with locally advanced rectal cancer (LARC) is based on a combination of chemo-radiotherapy (CRT) and surgery. The rate of distant recurrences remains over 25%. Circulating cell-free DNA (cfDNA) in plasma is a mixture
Publikováno v:
Annals of Oncology. 29:744-748
Background A large trial of postmenopausal women with breast cancer reported an imbalance in colorectal cancer events with aromatase inhibitors (AIs), compared with tamoxifen in the adjuvant setting. This unexpected signal was observed within 3 years